3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Breast Neoplasms
6
Colorectal Neoplasms
4
Ovarian Neoplasms
3
Neuroblastoma
3
Neoplasm Metastasis
3
Uveal Melanoma
2
Unspecified Adult Solid Tumor, Protocol Specific
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms, Male
2
Adenocarcinoma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Interventions
pembrolizumab
9
avelumab
8
Nivolumab
6
Ipilimumab
4
Radiotherapy
3
durvalumab
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Specimen Handling
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Interferon-beta
2
Cyclophosphamide
2
Biopsy
2
Bevacizumab
2
tremelimumab
1
sargramostim
1
sapanisertib
1
regorafenib
1
prednylidene
1
poly ICLC
1
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
lutetium Lu 177 dotatate
1
interferon gamma-1b
1
epacadostat
1
efineptakin alfa
1
deltacortene
1
decitabine and cedazuridine drug combination
1
bempegaldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Merkel Cell
×
sargramostim
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled